Coreline Soft Secures 12 Billion KRW Series C Funding... "Total Investment Raised Reaches 27 Billion KRW"

[Asia Economy Reporter Hyunseok Yoo] Coreline Soft announced on the 10th that it has completed a Series C investment of 12 billion KRW from five institutional investors.

This follows the Series B funding in July last year, which accumulated investments of 15 billion KRW. Five investors, including KDB Hanwha Digital Healthcare No.1 Private Equity Fund, NH-Aju KOSDAQ Scale-up Fund, and Timefolio Asset Management, joined the round. Having secured a total investment of 27 billion KRW, Coreline Soft plans to focus on elevating the quality of global medical services, primarily in Europe and the United States.

Coreline Soft, the only medical AI company selected as a national lung cancer screening solution provider for five consecutive years, supplies its products to over 100 medical institutions domestically and internationally, including Ningxia, the largest general hospital in China, National Taiwan University Hospital, Hokkaido University Hospital in Japan, and Leuven Hospital in Belgium.

It has also been selected as a solution provider for the EU LCS Trial (4ITLR), the largest lung cancer clinical screening project in Europe conducted over four years starting this year in six major European countries, as well as the German lung cancer screening project 'HANSE.' Additionally, Coreline Soft has established networks with Stanford University School of Medicine and Harvard Medical School’s training hospital (MGH), securing a dominant position in the field of pulmonary diseases.

The establishment of overseas subsidiaries is progressing smoothly. The European subsidiary has been established in Frankfurt, Germany, and the U.S. subsidiary is scheduled to be completed by September this year.

Its flagship product is AVIEW LCS PLUS, which automatically screens for lung cancer, chronic obstructive pulmonary disease, cardiovascular diseases, and more with a single chest CT scan. This technology enables simultaneous interpretation of chest-related diseases and is regarded as the most advanced in the field.

Jinkook Kim, CEO of Coreline Soft, stated, “Thanks to our lung diagnostic technology recognized both domestically and globally, we have secured a clear competitive advantage in the medical AI sector, enabling us to successfully complete the Series C investment. We will focus on expanding our global network and business through this investment.”

Coreline plans to expand the diagnostic scope of a single CT scan to the whole body. To this end, it is developing additional solutions targeting diseases identifiable from chest CT images. Having already completed the development of an interstitial lung disease solution, it is currently working on technologies for interstitial lung abnormalities (ILA) and bronchiectasis as indications.

Meanwhile, Coreline Soft aims to be listed on the KOSDAQ market through a technology special listing in the first half of next year. NH Investment & Securities has been selected as the lead underwriter, and Daishin Securities as the joint underwriter. The technology evaluation is currently underway.

This content was produced with the assistance of AI translation services.